We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,253

Off-label medicine: as bad as it sounds?
  • RPC
  • United Kingdom
  • June 13 2018

Consider this: the prescription your doctor wrote for you may not be "officially" approved for your illness. Before you panic, this may not be as


Two Enacted State Laws Permit Truthful Off-Label Promotion
  • Cooley LLP
  • USA
  • May 16 2018

Earlier this month, Tennessee House Bill 2220 (substituted for Senate Bill 2361) (Tennessee Law) was enacted, which provides, “A pharmaceutical


Boots on the Ground: PIL Task Force Targeting Opioid Providers in the War on Drugs
  • K&L Gates
  • USA
  • April 30 2018

Attorney General Jeff Sessions announced the creation of the Prescription Interdiction & Litigation (“PIL”) Task Force -- which Sessions described as


"Off-label" Cases Aren't Going Away - DOJ Sheds Light on Direction of Enforcement of Misbranding Rules Governing Medical Products
  • Venable LLP
  • USA
  • March 6 2018

On February 28, Ethan Davis, the U.S. Department of Justice's (DOJ) deputy assistant attorney general responsible for consumer protection, gave a


Off-label use of medicines: the CJEU on "by object" infringement under EU competition law
  • Taylor Wessing
  • European Union
  • February 21 2018

In November 2017, we reported on Advocate General Saugmandsgaard Øe's Opinion in Case C-17916 F. Hoffman-La Roche Ltd and Others v Autorità Garante


Two DOJ Memos to Impact Health Care False Claims Act Litigation
  • Dinsmore & Shohl LLP
  • USA
  • February 14 2018

As the new year started, two Department of Justice memoranda began circulating that may bring a change in the way the United States focuses its


EU Court ruling on how off-label use is to be analysed under competition law
  • White & Case LLP
  • European Union
  • February 14 2018

The highest EU court has held that an agreement to disseminate misleading information about the safety of a medicine being used off-label may restrict


Breaking News: TH v. Novartis - California Supreme Court Recognizes New Tort Duties as Traditional Limits Slide into the Sea
  • Reed Smith LLP
  • USA
  • December 21 2017

We posted our 2017 "Worst 10 decisions" list a day too soon, because the California Supreme Court issued its anticipated decision in TH v. Novartis


News Update EU - Life Sciences Special December 2017
  • Houthoff
  • United Kingdom, European Union, France
  • December 7 2017

On 20 November 2017, the EU Council announced that Amsterdam will be the new location for the European Medicines Agency (EMA) after the UK will


PMA Preemption & Fraud by OmissionConcealment
  • Reed Smith LLP
  • USA
  • November 29 2017

As our PMA preemption scorecard makes clear, warning claims are preempted under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), because the